Arrowhead Pharmaceuticals Inc. (ARWR)

29.63
0.19 0.65
NASDAQ : Health Technology
Prev Close 29.44
Open 29.66
Day Low/High 29.14 / 30.43
52 Wk Low/High 10.41 / 36.80
Volume 786.57K
Avg Volume 1.38M
Exchange NASDAQ
Shares Outstanding 95.30M
Market Cap 2.87B
EPS -0.70
P/E Ratio 62.39
Div & Yield N.A. (N.A)
Arrowhead Issues Open Letter To Shareholders

Arrowhead Issues Open Letter To Shareholders

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today issued the following open letter to shareholders from President and CEO, Christopher Anzalone, Ph.

'Fast Money' Recap: Relief About the Stock Market Rally

'Fast Money' Recap: Relief About the Stock Market Rally

The trading panel discussed where they are putting their money after the change in market direction.

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Arrowhead Research Corp. - ARWR

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Arrowhead Research Corp. - ARWR

The Rosen Law Firm announces that it is investigating potential securities claims against Arrowhead Research Corp.

Blame Arrowhead Management Entirely for Today's Epic Collapse

Blame Arrowhead Management Entirely for Today's Epic Collapse

CEOs of early stage biotech companies like Arrowhead cannot deliver nasty surprises to Wall Street, yet some inexplicable reason, Anzalone totally botched the job.

3 Stocks Pushing The Drugs Industry Lower

3 Stocks Pushing The Drugs Industry Lower

TheStreet highlights 3 stocks pushing the drugs industry lower today.

Arrowhead Research Sinks on Disappointing Hepatitis B Drug Data

Arrowhead Research Sinks on Disappointing Hepatitis B Drug Data

In an ongoing phase II study, ARC-520 dosed at 2 mg/kg induced a 0.3 log reduction in HBsAG, a measure of the presence of hepatitis B virus in the body.

Arrowhead To Present ARC-520 Phase 2a Data In Late-Breaking Session At AASLD Liver Meeting® 2014

Arrowhead To Present ARC-520 Phase 2a Data In Late-Breaking Session At AASLD Liver Meeting® 2014

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that data from the ongoing Phase 2a study of ARC-520, its RNAi therapeutic candidate for...

Arrowhead To Present At 10th Annual Meeting Of The Oligonucleotide Therapeutics Society

Arrowhead To Present At 10th Annual Meeting Of The Oligonucleotide Therapeutics Society

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that the Company is presenting at the 10 th Annual Meeting of the Oligonucleotide...

Notable Two Hundred Day Moving Average Cross - ARWR

Notable Two Hundred Day Moving Average Cross - ARWR

In trading on Wednesday, shares of Arrowhead Research Corp crossed below their 200 day moving average of $14.52, changing hands as low as $13.61 per share. Arrowhead Research Corp shares are currently trading off about 4.9% on the day.

Arrowhead Expands Management Team With Appointment Of Susan Boynton As Vice President Global Regulatory Affairs

Arrowhead Expands Management Team With Appointment Of Susan Boynton As Vice President Global Regulatory Affairs

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that Susan Boynton has been appointed Vice President, Global Regulatory Affairs.

Arrowhead To Present At BioCentury’s NewsMakers In The Biotech Industry Conference

Arrowhead To Present At BioCentury’s NewsMakers In The Biotech Industry Conference

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that Bruce Given, M.

3 Biotech Breakout Charts That Could See More Upside Next Week

3 Biotech Breakout Charts That Could See More Upside Next Week

three four to watch for more upside.

Strong On High Volume: Arrowhead Research (ARWR)

Strong On High Volume: Arrowhead Research (ARWR)

Trade-Ideas LLC identified Arrowhead Research (ARWR) as a strong on high relative volume candidate

Arrowhead Research Climbs +8.54% Midday, Is Up Over +50% YTD

Arrowhead Research Climbs +8.54% Midday, Is Up Over +50% YTD

Arrowhead Research Corp (NASDAQ:ARWR), dELiA*s, Inc. (NASDAQ:DLIA) and Avalon Rare Metals Inc (NYSEMKT:AVL) are today's top-gaining billionaire picks midday. The biggest losers are Repros Therapeut...

5 Stocks Poised for Big Breakouts

5 Stocks Poised for Big Breakouts

These stocks look ready to break out and trade higher from current levels.

Arrowhead Research (ARWR) Stock Rises on High Volume

Arrowhead Research (ARWR) Stock Rises on High Volume

Arrowhead Research (ARWR) surged Tuesday after Roche's $8.3 billion acquisition of InterMune (ITMN) led the biotech sector higher.

'Fast Money' Recap: Next Stop, S&P 2,100?

'Fast Money' Recap: Next Stop, S&P 2,100?

The trading panel looked at banks and the top buy and sell candidates for right now.

First Week of ARWR October 18th Options Trading

First Week of ARWR October 18th Options Trading

Investors in Arrowhead Research Corp saw new options become available this week, for the October 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ARWR options chain for the new October 18th contracts and identified one put and one call contract of particular interest.

5 Stocks Jumping on Unusual Volume

5 Stocks Jumping on Unusual Volume

Often when above-average volume moves into an equity, it precedes a large spike in volatility.

Stock To Watch: Arrowhead Research (ARWR) In Perilous Reversal

Stock To Watch: Arrowhead Research (ARWR) In Perilous Reversal

Trade-Ideas LLC identified Arrowhead Research (ARWR) as a "perilous reversal" (up big yesterday but down big today) candidate

ARWR November 22nd Options Begin Trading

ARWR November 22nd Options Begin Trading

Investors in Arrowhead Research Corp saw new options become available today, for the November 22nd expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 99 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

'Mad Money' Lightning Round: Don't Buy IBM Right Now

'Mad Money' Lightning Round: Don't Buy IBM Right Now

Cramer says he's avoiding Potbelly but likes Opko Health and Hawaiian Holdings.

Jim Cramer's 'Mad Money' Recap: Now That's More Like It

Jim Cramer's 'Mad Money' Recap: Now That's More Like It

When the consensus changes, the buyers change, too, and that's why Tuesday's stocks were being bought Wednesday, Cramer says.

Arrowhead Discloses First Human Hepatitis B Therapy Results

Arrowhead Discloses First Human Hepatitis B Therapy Results

The announcement is short on specific details but the Arrowhead drug, ARC-520, appears to have passed through its first clinical hurdle in hepatitis B patients relatively well.

Arrowhead Reports Fiscal 2014 Third Quarter Financial Results And Provides Update On ARC-520

Arrowhead Reports Fiscal 2014 Third Quarter Financial Results And Provides Update On ARC-520

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced financial results for its fiscal 2014 third quarter ended June 30, 2014 and provided an...

Bullish Two Hundred Day Moving Average Cross - ARWR

Bullish Two Hundred Day Moving Average Cross - ARWR

In trading on Monday, shares of Arrowhead Research Corp crossed above their 200 day moving average of $13.14, changing hands as high as $13.50 per share. Arrowhead Research Corp shares are currently trading up about 2% on the day.

Today's Dead Cat Bounce Stock Is Arrowhead Research (ARWR)

Today's Dead Cat Bounce Stock Is Arrowhead Research (ARWR)

Trade-Ideas LLC identified Arrowhead Research (ARWR) as a "dead cat bounce" (down big yesterday but up big today) candidate

Biotech Stock Mailbag: Arrowhead, Catalyst Pharma

Biotech Stock Mailbag: Arrowhead, Catalyst Pharma

Biotech columnist Adam Feuerstein answers readers' questions about health care.

Arrowhead To Report Fiscal 2014 Third Quarter Financial Results

Arrowhead To Report Fiscal 2014 Third Quarter Financial Results

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it will report its financial results for the fiscal 2014 third quarter ended June...

Trade-Ideas: Arrowhead Research (ARWR) Is Today's "Perilous Reversal" Stock

Trade-Ideas: Arrowhead Research (ARWR) Is Today's "Perilous Reversal" Stock

Trade-Ideas LLC identified Arrowhead Research (ARWR) as a "perilous reversal" (up big yesterday but down big today) candidate

TheStreet Quant Rating: C+ (Hold)